Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma

C. H. Hsu, T. S. Yang, C. Hsu, H. C. Toh, R. J. Epstein, L. T. Hsiao, P. J. Chen, Z. Z. Lin, T. Y. Chao, A. L. Cheng

研究成果: 雜誌貢獻文章同行評審

103 引文 斯高帕斯(Scopus)

摘要

Background: Molecularly targeted agents with anti-angiogenic activity, including bevacizumab, have demonstrated clinical activity in patients with advanced/metastatic hepatocellular carcinoma (HCC). This multicentre phase II study involving patients from several Asian countries sought to evaluate the safety and efficacy of bevacizumab plus capecitabine in this population. Methods: Histologically proven/clinically diagnosed advanced HCC patients received bevacizumab 7.5 mg kg-1 on day 1 and capecitabine 800 mg m-2 twice daily on days 1-14 every 3 weeks as first-line therapy.Results: A total of 45 patients were enrolled; 44 (96%) had extrahepatic metastasis and/or major vessel invasion and 30 (67%) had hepatitis B. No grade 3/4 haematological toxicity occurred. Treatment-related grade 3/4 non-haematological toxicities included diarrhoea (n=2, 4%), nausea/vomiting (n=1, 2%), gastrointestinal bleeding (n=4, 9%) and hand-foot syndrome (n=4, 9%). The overall response rate (RECIST) was 9% and the disease control rate was 52%. Overall, median progression-free survival (PFS) and overall survival (OS) were 2.7 and 5.9 months, respectively. Median PFS and OS were 3.6 and 8.2 months, respectively, for Cancer of the Liver Italian Programme (CLIP) score≤3 patients, and 1.4 and 3.3 months, respectively, for CLIP score 4 patients.Conclusion: The bevacizumab-capecitabine combination shows good tolerability and modest anti-tumour activity in patients with advanced HCC.

原文英語
頁(從 - 到)981-986
頁數6
期刊British Journal of Cancer
102
發行號6
DOIs
出版狀態已發佈 - 2010
對外發佈

ASJC Scopus subject areas

  • 腫瘤科
  • 癌症研究

指紋

深入研究「Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma」主題。共同形成了獨特的指紋。

引用此